Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STOK Stock Forecast 2025-2026
$11.84
Current Price
$647.52M
Market Cap
Buy 9
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to STOK Price Targets
+195.6%
To High Target of $35.00
+77.4%
To Median Target of $21.00
+26.7%
To Low Target of $15.00
STOK Price Momentum
+1.3%
1 Week Change
+2.7%
1 Month Change
-16.9%
1 Year Change
+7.3%
Year-to-Date Change
-26.7%
From 52W High of $16.15
+121.3%
From 52W Low of $5.35
📊 TOP ANALYST CALLS
Did STOK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stoke Therapeutics is one of their latest high-conviction picks.
Latest STOK Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, STOK has a bullish consensus with a median price target of $21.00 (ranging from $15.00 to $35.00). Currently trading at $11.84, the median forecast implies a 77.4% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew Fein at HC Wainwright & Co., projecting a 195.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STOK Analyst Ratings
9
Buy
1
Hold
0
Sell
STOK Price Target Range
Low
$15.00
Average
$21.00
High
$35.00
Current: $11.84
Latest STOK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STOK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 1, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| May 14, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $35.00 |
| Apr 9, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $47.00 |
| Mar 19, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $24.00 |
| Mar 18, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Feb 19, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $24.00 |
| Feb 18, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Feb 18, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $47.00 |
| Jan 8, 2025 | Needham | Joseph Stringer | Buy | Maintains | $22.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $35.00 |
| Dec 20, 2024 | Chardan Capital | Rudy Li | Buy | Initiates | $24.00 |
| Dec 10, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Nov 6, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $35.00 |
| Sep 11, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $35.00 |
| Aug 8, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Jul 11, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $17.00 |
| Jun 28, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| May 7, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $20.00 |
Stoke Therapeutics Inc. (STOK) Competitors
The following stocks are similar to Stoke Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Stoke Therapeutics Inc. (STOK) Financial Data
Stoke Therapeutics Inc. has a market capitalization of $647.52M with a P/E ratio of 14.5x. The company generates $190.91M in trailing twelve-month revenue with a 26.3% profit margin.
Revenue growth is +3,661.1% quarter-over-quarter, while maintaining an operating margin of +70.2% and return on equity of +20.5%.
Valuation Metrics
Market Cap
$647.52M
Enterprise Value
$266.56M
P/E Ratio
14.5x
PEG Ratio
-4.8x
Price/Sales
3.4x
Growth & Margins
Revenue Growth (YoY)
+3,661.1%
Gross Margin
N/A
Operating Margin
+70.2%
Net Margin
+26.3%
EPS Growth
+3,661.1%
Financial Health
Cash/Price Ratio
+55.3%
Current Ratio
8.4x
Debt/Equity
1.2x
ROE
+20.5%
ROA
+7.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stoke Therapeutics Inc. (STOK) Business Model
About Stoke Therapeutics Inc.
What They Do
Develops RNA-based treatments for genetic diseases.
Business Model
The company utilizes its proprietary TANGO platform to create RNA-based therapies that enhance protein production in target tissues. It primarily generates revenue through the development and commercialization of its innovative treatments for genetic disorders, focusing on rare conditions such as Dravet syndrome.
Additional Information
Stoke Therapeutics is positioned in the biopharmaceutical sector, offering novel therapeutic options for patients with significant unmet medical needs, particularly in central nervous system and liver disorders. Its pioneering approach has the potential to reshape treatment paradigms for genetic diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
128
CEO
Mr. Ian F. Smith A.C.A., C.P.A.
Country
United States
IPO Year
2019
Website
www.stoketherapeutics.comStoke Therapeutics Inc. (STOK) Latest News & Analysis
Latest News
Quick Summary
Phase 3 zorevunersen study shows improved cognition and behavior at Week 68, supporting key secondary endpoints in the EMPEROR study, differing from natural history data.
Why It Matters
Positive Phase 3 trial results for zorevunersen indicate potential cognitive and behavioral improvements, boosting confidence in the drug's efficacy and prospects for market approval, impacting stock valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Stoke Therapeutics and Biogen presented analysis data for the Phase 3 EMPEROR study, assessing zorevunersen's dosing regimen. This data supports the study's design.
Why It Matters
The announcement signals progress in Stoke Therapeutics' collaboration with Biogen, potentially influencing stock performance and investor confidence in their upcoming Phase 3 study results.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stoke Therapeutics (Nasdaq: STOK) announced the grant of stock options for 37,200 shares to two new employees, effective June 16, 2025. The company focuses on RNA medicine for Dravet syndrome.
Why It Matters
Stoke Therapeutics' stock option grant indicates confidence in future growth and potential success of its lead drug, zorevunersen. Positive developments in biotech can drive stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stoke Therapeutics is advancing RNA therapies for Dravet Syndrome and other conditions, backed by partnerships with Biogen and Acadia. The company faces high short interest and volatility.
Why It Matters
Stoke Therapeutics' innovative RNA therapies and strong partnerships enhance growth potential, but high short interest and volatility present risks that could impact stock performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Stoke Therapeutics (Nasdaq: STOK) is developing zorevunersen, a potential treatment for Dravet syndrome. CEO Ian F. Smith will present at the Jefferies Global Healthcare Conference on June 7.
Why It Matters
Stoke Therapeutics' presentation at a major healthcare conference could attract investor interest, potentially impacting stock price and future funding opportunities for its innovative therapies.
Source: Business Wire
Market Sentiment:
Neutral
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
1 month ago
Quick Summary
Stoke Therapeutics (STOK) has a consensus price target indicating a 132.4% upside potential, supported by recent upward revisions in earnings estimates.
Why It Matters
The 132.4% upside potential indicates significant growth expectations for Stoke Therapeutics, while rising earnings estimates suggest short-term stock price increases.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About STOK Stock
What is Stoke Therapeutics Inc.'s (STOK) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Stoke Therapeutics Inc. (STOK) has a median price target of $21.00. The highest price target is $35.00 and the lowest is $15.00.
Is STOK stock a good investment in 2026?
According to current analyst ratings, STOK has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STOK stock?
Wall Street analysts predict STOK stock could reach $21.00 in the next 12 months. This represents a 77.4% increase from the current price of $11.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stoke Therapeutics Inc.'s business model?
The company utilizes its proprietary TANGO platform to create RNA-based therapies that enhance protein production in target tissues. It primarily generates revenue through the development and commercialization of its innovative treatments for genetic disorders, focusing on rare conditions such as Dravet syndrome.
What is the highest forecasted price for STOK Stoke Therapeutics Inc.?
The highest price target for STOK is $35.00 from Andrew Fein at HC Wainwright & Co., which represents a 195.6% increase from the current price of $11.84.
What is the lowest forecasted price for STOK Stoke Therapeutics Inc.?
The lowest price target for STOK is $15.00 from at , which represents a 26.7% increase from the current price of $11.84.
What is the overall STOK consensus from analysts for Stoke Therapeutics Inc.?
The overall analyst consensus for STOK is bullish. Out of 13 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are STOK stock price projections?
Stock price projections, including those for Stoke Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 6:43 PM UTC